Tilade has been approved to extend its application to children ages six to eleven. It is an inhaled anti inflammatory drug indicated as maintenance therapy for mild to moderate bronchial asthma. Tilade was previously approved for patients 12 and older.
Tilade can be used in conjunction with inhaled corticosteroids, and inhaled and oral bronchodilators. It is not recommended for the reversal of acute bronchospasm.
The results of an 8 week double blind, parallel group study involving 146 children ages 6 11 demonstrated that Tilade controlled asthma symptoms and reduced the need for patients to use a rescue bronchodilator. There was also a statistically significant difference, in favor of Tilade, for all symptom scores (daytime asthma, sleep disturbance, daytime cough, morning asthma, parent's opinion, clinician's opinion, and bronchodilator use).
Adverse effects reported were unpleasant taste, rhinitis, nausea, vomiting and abdominal pain.
The Tilade (nedocromil sodium) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.